MedPage Today August 7, 2024
Joyce Frieden

— Competitors say their per-member, per-month payment model is fairer to employers and insurers

As the Federal Trade Commission (FTC) and Congress turn their attention to the business practices of pharmacy benefit managers (PBMs), companies are springing up to provide alternative ways for employers to manage their drug benefits.

Under the traditional model that has been used by the “Big Three” PBMs — CVS/Caremark, ExpressScripts, and OptumRx, which together comprise about 80% of the market — the PBM made its money in several ways, including through rebates — discounts — from drug manufacturers, and “spread pricing,” in which the PBM charges employers and insurers more for the drug than it pays to the pharmacy. PBMs have also used other tactics,...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Employer, Insurance, Pharma, Pharma / Biotech
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal

Share This Article